|Bid||7,197.00 x 0|
|Ask||7,198.00 x 0|
|Day's Range||7,040.00 - 7,311.59|
|52 Week Range||5,626.00 - 8,227.88|
|Beta (5Y Monthly)||0.22|
|PE Ratio (TTM)||70.02|
|Earnings Date||Apr 29, 2020|
|Forward Dividend & Yield||2.18 (3.06%)|
|Ex-Dividend Date||Feb 27, 2020|
|1y Target Est||78.83|
J&J (JNJ) to begin human clinical studies on coronavirus vaccine candidate in September. Sanofi (SNY) begins outside U.S. study on Kevzara for severe COVID-19 infection.
A rally in crude-oil futures sent the European energy sector higher on Tuesday, helping markets recover some lost ground from the rough start to the second quarter.
RedHill to promote Movantik® in the U.S. to expanded call points, including gastroenterologists, primary care physicians and additional specialists, along with Talicia® and.
Citi’s global health-care, strategy and economics teams say governments and health-care providers will be able to supply 60% of U.S. individuals of working age with antibody tests by the end of April, and 95% by the end of May.
AstraZeneca's (AZN) Imfinzi gets FDA approval as first-line treatment for extensive-stage small cell lung cancer patients. A phase III study on Farxiga in CKD patients meets endpoint earlier than expected.
Results from two subgroup analyses of the Phase IV independent TWILIGHT trial funded by AstraZeneca showed BRILINTA (ticagrelor) monotherapy reduced the risk of clinically relevant bleeding over 12 months compared to aspirin plus BRILINTA in high-risk coronary patients.
The Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) Phase III trial for FARXIGA (dapagliflozin) in patients with chronic kidney disease (CKD) will be stopped early following a recommendation from an independent Data Monitoring Committee (DMC) based on its determination of overwhelming efficacy.
AstraZeneca today announced that IMFINZI® (durvalumab) has been approved in the US as a 1st-line treatment for adult patients with extensive-stage small cell lung cancer (ES-SCLC) in combination with standard-of-care (SoC) chemotherapies, etoposide and either carboplatin or cisplatin (platinum-etoposide).
An interim study analysis showed that patients on Farxiga, known as Forxiga outside North America, had better renal function and were less likely to die from heart of kidney disease than a control group on placebo, the company said on in a statement on Monday. Farxiga, among AstraZeneca's top five drugs by sales, was first developed as a diabetes drug as it causes the kidneys to expel blood sugar from the body through urine but it has shown promise as a heart failure treatment, even among non-diabetic patients.
The treatment, when combined with chemotherapy, was approved by the U.S. Food and Drug Administration for adult patients with extensive-stage small cell lung cancer, the British drugmaker said. AstraZeneca has already carved out a niche for Imfinzi, which enables the immune system to detect and attack certain cancer cells, in the more common non-small cell lung cancer (NSCLC) setting, with approval for tumours that have only spread in the chest. In the small-cell type of cancer, Astra is seeking to catch up with Roche, whose immunotherapy Tecentriq won U.S. approval for the disease type a year ago.
AstraZeneca makes it look almost easy. In the middle of the past decade, the Anglo-Swedish pharmaceutical company fell down the biggest patent cliff in the industry. Separately its Farxiga treatment was found to show “overwhelming efficacy” in patients with chronic kidney disease (CKD).
New data from a sub-analysis of the landmark Phase III DAPA-HF (Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure) trial showed that AstraZeneca’s FARXIGA (dapagliflozin) reduced the incidence of the primary composite endpoint of heart failure (HF) worsening or cardiovascular (CV) death compared to placebo, in patients with heart failure with reduced ejection fraction (HFrEF), irrespective of their background therapy (i.e. other medications for heart failure).
The Japanese regulatory body nods to AstraZeneca's (AZN) Lokelma for addressing patients with hyperkalaemia. The company collaborates with Silence Therapeutics for siRNA therapeutics.
The Zacks Analyst Blog Highlights: Walmart, NVIDIA, AstraZeneca, Goldman Sachs and Global Payments
AstraZeneca PLC (LON:AZN) shareholders might be concerned after seeing the share price drop 12% in the last quarter...
AstraZeneca (AZN)/Merck's (MRK) study evaluating cediranib added to Lynparza fails to meet the primary endpoint of PFS in patients with platinum-sensitive relapsed ovarian cancer
AstraZeneca and Merck said an ovarian cancer treatment failed in Phase 3 testing on Thursday — leading AZN stock and MRK stock to tumble. Pharma stocks broadly fell on Thursday.
Lilly (LLY) signs deal with AbCellera to co-develop antibody therapies to treat COVID-19. AbbVie (ABBV) supports studies evaluating Kaletra for treating COVID-19.
Coronavirus is probably the 1 concern in investors' minds right now. It should be. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW. We predicted that a US recession is imminent and US stocks will go down by at least 20% in the next 3-6 […]
Moody's Investors Service, ("Moody's") has today affirmed the senior unsecured ratings of Investor AB ('Investor') at Aa3. Today's rating affirmation reflects Investor AB's very low market value leverage of below 3% at year-end 2019 and its strong liquidity position with SEK25 billion of cash on balance sheet at 31st December 2019. Investor's cash on balance sheet at 31st December 2019 covers debt maturities up to 2033 and its average maturity profile was around 11 years at year-end 2019.